Target Price | CHF105.06 |
Price | CHF101.16 |
Potential | 3.86% |
Number of Estimates | 23 |
23 Analysts have issued a price target Novartis 2026 . The average Novartis target price is CHF105.06. This is 3.86% higher than the current stock price. The highest price target is CHF126.00 24.56% , the lowest is CHF80.80 20.13% . | |
A rating was issued by 31 analysts: 13 Analysts recommend Novartis to buy, 14 to hold and 4 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Novartis stock has an average upside potential 2026 of 3.86% . Most analysts recommend the Novartis stock at Hold. |
24 Analysts have issued a sales forecast Novartis 2025 . The average Novartis sales estimate is CHF45.1b . This is 2.80% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF48.7b 10.98% , the lowest is CHF41.4b 5.80% .
This results in the following potential growth metrics:
2024 | CHF41.4b | 10.85% |
---|---|---|
2025 | CHF45.1b | 9.01% |
2026 | CHF46.3b | 2.49% |
2027 | CHF47.6b | 3.01% |
2028 | CHF49.3b | 3.42% |
2029 | CHF50.8b | 3.00% |
2030 | CHF51.9b | 2.31% |
2031 | CHF49.0b | 5.57% |
2032 | CHF45.0b | 8.20% |
20 Analysts have issued an Novartis EBITDA forecast 2025. The average Novartis EBITDA estimate is CHF18.1b . This is 21.78% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF19.8b 33.03% , the lowest is CHF13.7b 8.17% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | CHF13.2b | 26.63% |
---|---|---|
2025 | CHF18.1b | 37.09% |
2026 | CHF18.5b | 2.15% |
2027 | CHF19.2b | 3.55% |
2028 | CHF20.9b | 8.90% |
2029 | CHF21.8b | 4.12% |
2030 | CHF23.7b | 8.86% |
2031 | CHF18.6b | 21.47% |
2032 | CHF16.4b | 11.98% |
2024 | 31.96% | 14.24% |
---|---|---|
2025 | 40.19% | 25.76% |
2026 | 40.06% | 0.32% |
2027 | 40.27% | 0.52% |
2028 | 42.40% | 5.29% |
2029 | 42.86% | 1.08% |
2030 | 45.61% | 6.42% |
2031 | 37.93% | 16.84% |
2032 | 36.36% | 4.14% |
25 Novartis Analysts have issued a net profit forecast 2025. The average Novartis net profit estimate is CHF14.1b . This is 28.77% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF15.0b 37.55% , the lowest is CHF12.6b 15.32% .
This results in the following potential growth metrics and future Net Margins:
2024 | CHF9.6b | 19.59% |
---|---|---|
2025 | CHF14.1b | 47.24% |
2026 | CHF14.6b | 3.96% |
2027 | CHF15.8b | 7.89% |
2028 | CHF16.6b | 5.22% |
2029 | CHF17.2b | 3.76% |
2030 | CHF17.9b | 4.10% |
2031 | CHF18.7b | 3.96% |
2032 | CHF16.9b | 9.36% |
2024 | 23.09% | 27.46% |
---|---|---|
2025 | 31.19% | 35.10% |
2026 | 31.63% | 1.41% |
2027 | 33.13% | 4.74% |
2028 | 33.70% | 1.72% |
2029 | 33.95% | 0.74% |
2030 | 34.55% | 1.77% |
2031 | 38.04% | 10.10% |
2032 | 37.55% | 1.29% |
25 Analysts have issued a Novartis forecast for earnings per share. The average Novartis EPS is CHF7.27 . This is 30.52% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF7.77 39.50% , the lowest is CHF6.51 16.88% .
This results in the following potential growth metrics and future valuations:
2024 | CHF4.70 | 17.25% |
---|---|---|
2025 | CHF7.27 | 54.68% |
2026 | CHF7.56 | 3.99% |
2027 | CHF8.15 | 7.80% |
2028 | CHF8.58 | 5.28% |
2029 | CHF8.90 | 3.73% |
2030 | CHF9.27 | 4.16% |
2031 | CHF9.63 | 3.88% |
2032 | CHF8.73 | 9.35% |
Current | 18.16 | 18.12% |
---|---|---|
2025 | 13.91 | 23.41% |
2026 | 13.38 | 3.81% |
2027 | 12.41 | 7.25% |
2028 | 11.79 | 5.00% |
2029 | 11.36 | 3.65% |
2030 | 10.92 | 3.87% |
2031 | 10.50 | 3.85% |
2032 | 11.58 | 10.29% |
Based on analysts' sales estimates for 2025, the Novartis stock is valued at an EV/Sales of 4.74 and an P/S ratio of 4.28 .
This results in the following potential growth metrics and future valuations:
Current | 4.87 | 17.04% |
---|---|---|
2025 | 4.74 | 2.74% |
2026 | 4.62 | 2.43% |
2027 | 4.49 | 2.93% |
2028 | 4.34 | 3.31% |
2029 | 4.21 | 2.91% |
2030 | 4.12 | 2.26% |
2031 | 4.36 | 5.90% |
2032 | 4.75 | 8.93% |
Current | 4.40 | 19.08% |
---|---|---|
2025 | 4.28 | 2.73% |
2026 | 4.18 | 2.43% |
2027 | 4.06 | 2.92% |
2028 | 3.92 | 3.31% |
2029 | 3.81 | 2.91% |
2030 | 3.72 | 2.26% |
2031 | 3.94 | 5.90% |
2032 | 4.29 | 8.93% |
Analyst | Rating | Action | Date |
---|---|---|---|
JEFFERIES |
Hold
➜
Hold
|
Unchanged | Jul 16 2025 |
TD COWEN |
Hold
➜
Hold
|
Unchanged | Jul 16 2025 |
GUGGENHEIM SECURITIES LLC |
Neutral
➜
Neutral
|
Unchanged | Jul 16 2025 |
ARGUS RESEARCH CORPORATION |
Hold
➜
Hold
|
Unchanged | Jul 10 2025 |
BERENBERG |
Hold
➜
Hold
|
Unchanged | Jul 08 2025 |
ROTHSCHILD & CO REDBURN |
Sell
➜
Sell
|
Unchanged | Jul 03 2025 |
DAY BY DAY |
Buy
➜
Hold
|
Downgrade | Jun 08 2025 |
Analyst Rating | Date |
---|---|
Unchanged
JEFFERIES:
Hold
➜
Hold
|
Jul 16 2025 |
Unchanged
TD COWEN:
Hold
➜
Hold
|
Jul 16 2025 |
Unchanged
GUGGENHEIM SECURITIES LLC:
Neutral
➜
Neutral
|
Jul 16 2025 |
Unchanged
ARGUS RESEARCH CORPORATION:
Hold
➜
Hold
|
Jul 10 2025 |
Unchanged
BERENBERG:
Hold
➜
Hold
|
Jul 08 2025 |
Unchanged
ROTHSCHILD & CO REDBURN:
Sell
➜
Sell
|
Jul 03 2025 |
Downgrade
DAY BY DAY:
Buy
➜
Hold
|
Jun 08 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.